| Name | Title | Contact Details |
|---|
First branch of Banka Kombëtare Tregtare was established in Durrës on 29 November 1925, in the historical building where todays BKT Durrës Branch is situated. This building actually represents the oldest Albanian financial institution in the country. Banka Kombëtare Tregtare (BKT), with todays name, was established in January 1993, after the merging of the Albanian Commercial Bank (ACB) and the National Bank of Albania (NBA). The NBA on the other hand was established in 1992 as a result of a second sub-division of the State Bank of Albania. The NBA was set up to manage the domestic trading activity of the State-owned entities. The assets and liabilities from the activities of these two entities were transferred to BKT accounts since it was first established. Banka Kombëtare Tregtare was established as a Joint Stock Company in July 1997, with assets reaching ALL 2.7 billion. In February 2003, with the decision of the Shareholders General Meeting, the paid-up capital reached the amount of US$ 14, 64 million, turning BKT into the most capitalized bank in the whole Albanian banking system. The year 2006 started with a new vision for BKT. With the authorization of the Bank of Albania and pursuant to the specific court decision issued on June 9, 2006, it was approved the transfer of 60% plus 2 of the BKT shares possessed by Kent Bank in favour of Calik-Seker Konsorsiyum Yatirim A.S. On September 3, BKT opened its branch in Kosova and since that time, BKT Kosova has already opened 27 branches, ranking Banka Kombëtare Tregtare as the largest Albanian bank in the region. On June 30, 2009 Çalik Financial Services buys to IFC and EBRD shares being in this way the only BKT shareholder owning 100 % of the shares. On 30th April 2018 Banka Kombëtare Tregtare Kosova Branch, changes its status from Branch of a Foreign Bank to a subsidiary Bank. Now, its banking license has changed from Banka Kombëtare Tregtare Kosova Branch, to Banka Kombëtare Tregtare Kosovë J.S.C.
Why Wait? JOIN OUR REVOLUTION IN FURNITURE! Our mission is powerful and we execute with precision: Furnish your entire office with shipping in just 48 hours. With design support, 3D renders and fast quotes, you can say goodbye to the days of waiting 6-8 weeks (or more!) to furnish your office. Backed by a great warranty, you can count on us to deliver quality products, at rocket speeds. The stars have aligned for us to be your go-to furniture manufacturer! Stay connected here to learn about new products coming into our orbit this year and beyond.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Hancock and Moore Fine Furniture